OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery
August 08, 2023 06:30 ET
|
Oculis Holding AG
Once daily OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgeryOPTIMIZE’s results follow the positive and statistically...
First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
August 02, 2023 08:00 ET
|
Oculis Operations Sarl
LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME)Cystoid Macular Edema (CME) can result...
Oculis Announces to Present at Upcoming August Investor Conferences
July 26, 2023 08:00 ET
|
Oculis SA
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Present at OIS Retina Innovation Summit
July 19, 2023 08:00 ET
|
Oculis SA
ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
June 26, 2023 08:00 ET
|
Oculis SA
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal investigators, Dr. David S. Boyer and Dr....
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
June 13, 2023 16:01 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
June 12, 2023 08:00 ET
|
Oculis SA
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson. OPTIREACH is behind Oculis’...
Oculis to Participate in Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
May 31, 2023 23:59 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
May 30, 2023 07:06 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...